Holen Sie sich die Stockscreener-App
84.11
2.14%
-1.84
Handel nachbörslich:
84.00
-0.11
-0.13%
Schlusskurs vom Vortag:
$85.95
Offen:
$84.14
24-Stunden-Volumen:
283.57K
Relative Volume:
1.74
Marktkapitalisierung:
$3.85B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-10.87%
1M Leistung:
-18.02%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$80.00
$86.50
1-Wochen-Bereich:
$80.00
$96.84
52-Wochen-Spanne:
$80.00
$138.70
Billiontoone Inc Stock (BLLN) Company Profile
Firmenname
Billiontoone Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie BLLN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLLN
Billiontoone Inc
|
84.11 | 3.93B | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
636.30 | 232.57B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
242.05 | 165.52B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
696.46 | 54.78B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
241.40 | 39.80B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
139.77 | 38.51B | 6.95B | 1.30B | 1.15B | 4.5696 |
Billiontoone Inc Stock (BLLN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-06 | Eingeleitet | Guggenheim | Buy |
| 2025-12-01 | Eingeleitet | BTIG Research | Buy |
| 2025-12-01 | Eingeleitet | JP Morgan | Overweight |
| 2025-12-01 | Eingeleitet | Jefferies | Hold |
| 2025-12-01 | Eingeleitet | Piper Sandler | Overweight |
| 2025-12-01 | Eingeleitet | Stifel | Buy |
| 2025-12-01 | Eingeleitet | Wells Fargo | Equal Weight |
| 2025-12-01 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Billiontoone Inc Aktie (BLLN) Neueste Nachrichten
Analysts Offer Insights on Healthcare Companies: BillionToOne, Inc. Class A (BLLN) and Dexcom (DXCM) - The Globe and Mail
BillionToOne Inc (BLLN) Trading Down 4.99% on Jan 20 - GuruFocus
BillionToOne Inc (BLLN) Stock Price Down 3.55% on Jan 16 - GuruFocus
BillionToOne integrates prenatal and oncology tests with Epic EHR By Investing.com - Investing.com Nigeria
BillionToOne Integrates Prenatal and Oncology Tests into Epic Aura Diagnostics Suite - TipRanks
BillionToOne to Integrate Testing Portfolio With Epic's Diagnostics Suite - marketscreener.com
BillionToOne, Inc. Announces Collaboration with Epic to Expand Prenatal and Oncology Testing Across Healthcare - marketscreener.com
BillionToOne integrates prenatal and oncology tests with Epic EHR - Investing.com
BillionToOne Announces Collaboration with Epic to Expand Prenatal and Oncology Testing Across Healthcare - PR Newswire
What's Going On With BillionToOne Shares Tuesday?BillionToOne (NASDAQ:BLLN) - Benzinga
BillionToOne reaffirms 2025 guidance, projects 40-45% revenue growth in 2026 - Investing.com Nigeria
BillionToOne Stock (+15%): Strong '26 Guidance Spurs Re-Rate - Trefis
BillionToOne: Reaffirmed Growth Targets and Upside to 2026 Support Reiterated Buy Rating - TipRanks
BillionToOne reaffirms FY25 guidance - MSN
(BLLN) BillionToOne Expects 2026 Total Revenue Range $415M to $430M, vs. FactSet Est of $402.3M - marketscreener.com
BillionToOne Issues Strong 2026 Growth and Profit Outlook - TipRanks
Billiontoone provides guidance for 2026 - marketscreener.com
BillionToOne Provides Guidance for 2026 - The Manila Times
Billiontoone Provides Guidance For 2026 - TradingView — Track All Markets
Billiontoone, Inc. Provides Earnings Guidance for 2026 - marketscreener.com
BillionToOne, Inc. (NASDAQ:BLLN) Q3 2025 earnings call transcript - MSN
BillionToOne initiated with a Buy at Stifel - MSN
BillionToOne, Inc.: Revenue and Earnings Analysts Forecasts Revisions | BPJH | US0901681058 - marketscreener.com
January 2026's Top Growth Companies With Insider Confidence - Yahoo Finance
After tax other income/expense of BillionToOne, Inc. Class A – BX:BLLN - TradingView — Track All Markets
BillionToOne initiated with a buy at Guggenheim - MSN
BillionToOne, Inc. Announces Selection of Northstar Select as New Liquid Biopsy Test for LC-SCRUM-TRY Clinical Study at National Cancer Center Hospital East - marketscreener.com
BillionToOne Announces Selection of Northstar Select® as the new - GuruFocus
BillionToOne Announces Selection of Northstar Select® as the new liquid biopsy test for LC-SCRUM-TRY clinical study at National Cancer Center Hospital East - PR Newswire
3 Stocks Estimated To Be Up To 48.4% Below Intrinsic Value - Yahoo Finance
BillionToOne (BLLN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
BillionToOne Earnings Notes - Trefis
Med-tech IPOs shoot for the stars in 2025 - BioWorld MedTech
BillionToOne to Participate in the 44th Annual J.P. Morgan Healthcare Conference - 富途牛牛
2 New IPO Stocks Enter the Fray; J.P. Morgan Says ‘Buy’ - Yahoo Finance
BillionToOne stock in focus before Monday open after Friday jump, JPMorgan conference next - ts2.tech
BillionToOne (BLLN) Stock Update: Friday Rally, Analyst Price Targets, and the Next Catalysts Before Nasdaq Reopens - ts2.tech
BillionToOne Stock (NASDAQ: BLLN) News: Weekend Market Wrap, Analyst Targets, and What to Watch Before Monday’s Open - ts2.tech
BillionToOne Stock (NASDAQ: BLLN) Rises Into the Weekend as Analyst Targets Point Higher — What Investors Need to Know Before Monday - ts2.tech
Should I buy BillionToOne, Inc. (BLLN) - Zacks Investment Research
Evommune and BillionToOne climb on trading debut - MSN
BillionToOne (BLLN) Is Down 6.7% After Joining the S&P Total Market IndexWhat's Changed - simplywall.st
BillionToOne falls -5.5% - MSN
BillionToOne: An Interesting Set-Up Into 2026 - Seeking Alpha
BillionToOne Stock (NASDAQ: BLLN) News, Forecasts, and Analyst Outlook for December 22, 2025 - ts2.tech
BillionToOne Adds Genmab CFO Anthony Pagano to Board, Names Him Audit Chair - TipRanks
Analysts Are Bullish on These Healthcare Stocks: Gilead Sciences (GILD), BillionToOne, Inc. Class A (BLLN) - The Globe and Mail
Finanzdaten der Billiontoone Inc-Aktie (BLLN)
Es liegen keine Finanzdaten für Billiontoone Inc (BLLN) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
3.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):